AlphaMeld Corporation
Felipe Villena, PhD, is a skilled computational biologist currently working at InveniAI since July 2022, where expertise in RNA-seq analysis has led to the identification of differentially expressed gene signatures related to various diseases. Prior experience as a biomarker scientist at Novigenix SA involved developing R-based workflows to enhance Next Generation Sequencing data quality for biomarker discovery. At ETH Zürich, Felipe held roles as a postdoctoral research scientist and PhD student, focusing on single-cell RNA sequencing, metabolomics analysis, and system-biology approaches to advance understanding of pancreatic beta cell proliferation in response to insulin resistance. Academic credentials include a PhD in Molecular Translational Biomedicine from ETH Zürich and a Master's degree in Biochemistry from Universidad Andres Bello, with ongoing training in data science at DataCamp.
This person is not in any offices
AlphaMeld Corporation
Headquartered in Guilford, CT, AlphaMeld® Corporation (a wholly owned subsidiary of InveniAI LLC) stands as a global frontrunner in the application of AI, machine learning, and generative AI tools, catalyzing innovation throughout drug discovery and development. With a mission to identify and expedite transformative therapies for diseases with unmet medical needs, the company utilizes its cutting-edge AlphaMeld platform to extract valuable insights from petabytes of diverse data sets, propelling the creation of groundbreaking drug programs. The company's pioneering approach is underscored by successful collaborations with industry leaders and drug spinouts, solidifying its position as a trailblazer in the realm of AI-driven drug discovery. About The AlphaMeld® Platform The AlphaMeld platform employs a comprehensive approach to generate testable hypotheses, considering factors such as the ideal mode of pharmacotherapy, disease severity, gene ontology, disease pathways, proteinopathies, standard of care, emerging innovation, and enabling technologies. This is done while factoring in medical, scientific, strategic, and commercial considerations.